GO:0015937 coenzyme A biosynthetic process guide

Coenzyme A (CoA) is an essential metabolic cofactor that carries acyl groups in hundreds of reactions, and the coenzyme A biosynthetic process (GO:0015937) is the enzymatic route that assembles it from pantothenate (vitamin B5), cysteine and ATP. The pathway is conserved from bacteria to humans and proceeds through a canonical five-step sequence: pantothenate phosphorylation by pantothenate kinase (PANK), condensation with cysteine by phosphopantothenoylcysteine synthetase (PPCS), decarboxylation by phosphopantothenoylcysteine decarboxylase (PPCDC), adenylation by phosphopantetheine adenylyltransferase (COASY/PPAT domain), and final dephosphorylation by dephospho-CoA kinase (COASY/DPCK domain) to yield CoA. Because CoA is the obligate acyl donor for fatty acid oxidation and synthesis, the TCA cycle, and protein acylation, its biosynthesis sits at the intersection of energy homeostasis, redox balance and gene regulation. Researchers study GO:0015937 because its disruption produces measurable metabolic, epigenetic and cell-fate phenotypes. In mammalian cells, CoA biosynthetic enzymes are distributed between cytosol, mitochondria and peroxisomes, and flux through the pathway is tuned to nutrient status and to the demand for acyl-CoA pools. Mutations in PANK2 and COASY cause inherited disorders of CoA biosynthesis with prominent neurodegeneration and brain iron accumulation, while altered CoA metabolism has been linked to ferroptosis sensitivity and to gut microbial community dynamics. The pathway is therefore both a basic metabolic module and a tractable target for CRISPR-based functional genomics. This article summarizes the QuickGO-annotated term GO:0015937, its enzymatic steps, the genes and proteins involved, its regulation, its disease connections, and the experimental methods, including CRISPR knockout, point-mutation, knock-in and overexpression models, that are used to interrogate it.

GO:0015937, coenzyme A biosynthetic process, is the biological process in which the cell synthesizes coenzyme A from pantothenate and cysteine through a defined series of enzymatic reactions. The pathway converts pantothenate to 4'-phosphopantothenate, then to 4'-phosphopantothenoylcysteine, then to 4'-phosphopantetheine, then to dephospho-CoA, and finally to coenzyme A. The term covers the canonical de novo route and, in some organisms, salvage steps that recycle pathway intermediates.

Coenzyme A is required for acyl-group transfer in fatty acid oxidation and synthesis, the TCA cycle, amino acid catabolism and protein acylation, so the biosynthetic process that supplies it is a central node of cellular metabolism. Defects in GO:0015937 cause inherited neurometabolic disease, alter ferroptosis sensitivity, and shape gut microbial metabolic output, making the pathway relevant to neurobiology, cancer metabolism and microbiome research.

The following genes and proteins are the principal enzymes, transporters and regulators associated with GO:0015937 and its CoA-related metabolic network.

CoA biosynthesis is regulated primarily at the first committed step. Pantothenate kinase (PANK) is feedback-inhibited by CoA and acyl-CoA, so when acyl-CoA pools rise, flux into GO:0015937 is reduced. In mammalian cells, PANK isoforms differ in subcellular localization and in their sensitivity to feedback inhibition, allowing compartment-specific control of CoA synthesis. Nutrient and hormonal signals that alter acetyl-CoA and acyl-CoA levels therefore indirectly tune pathway flux, and the bifunctional COASY enzyme couples the final two steps, which may coordinate their activities. In bacteria, salvage and uptake systems add a further layer of regulation over intracellular CoA pools.

Biallelic mutations in PANK2 cause pantothenate kinase-associated neurodegeneration (PKAN), the most common NBIA subtype, and mutations in COASY cause COASY protein-associated neurodegeneration (CoPAN). These inherited disorders of CoA biosynthesis demonstrate that GO:0015937 is required for neuronal survival and that its failure produces iron accumulation and progressive neurodegeneration. Disease models have been used to test pantothenate and CoA precursor supplementation as therapeutic strategies.

CoA availability influences sensitivity to ferroptosis, an iron-dependent form of cell death. CoA mitigates cystine-deprivation-induced ferroptosis by suppressing the iron-starvation response, linking GO:0015937 to redox and iron homeostasis. This connection makes CoA biosynthetic enzymes candidate modifiers in cancer and degenerative contexts where ferroptosis contributes to pathology.

CoA and acyl-CoA species are substrates for post-translational acylation, including acetylation, succinylation and malonylation, which regulate enzyme activity, chromatin state and signaling. Because GO:0015937 determines the size and composition of acyl-CoA pools, its dysfunction can propagate to epigenetic and metabolic disease phenotypes.

CoA metabolism in gut bacteria is a key driver of microbiota dynamics and of host metabolic profiles, indicating that microbial GO:0015937 activity can influence community composition and metabolite output. This has implications for microbiome-based interventions and for understanding host-microbe metabolic exchange.

Direct measurement of CoA and acyl-CoA species by LC-MS/MS is the primary readout for GO:0015937 activity, and it can be combined with stable-isotope-labeled pantothenate to trace flux through the pathway. These assays distinguish free CoA from acetyl-CoA, malonyl-CoA and other acyl-CoA pools that report pathway output.

Knockout of PANK2, COASY, PPCS or PPCDC followed by wild-type or mutant cDNA rescue is a standard approach to establish causality for GO:0015937 in cell phenotypes. Patient-derived variants can be modeled by point-mutation knock-in to test whether specific alleles impair CoA synthesis.

RNA-seq and quantitative proteomics can reveal how loss of CoA biosynthesis remodels metabolic gene expression and enzyme abundance, including compensatory changes in fatty acid oxidation and lipogenesis. These methods help connect GO:0015937 to downstream acylation and signaling networks.

Bacterial systems such as Bacillus subtilis allow dissection of salvage and uptake routes that complement the canonical pathway, and gut microbiome studies link microbial CoA metabolism to host metabolic profiles. Comparative models help identify conserved and organism-specific features of GO:0015937.

Researchers studying coenzyme A biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in CoA supply, acyl-CoA pools or downstream disease phenotypes, and to distinguish loss-of-function from gain-of-function or variant-specific effects. EDITGENE provides the CRISPR cell models and screening services required to build that evidence chain rigorously.

GO:0015937, coenzyme A biosynthetic process, is a compact but essential metabolic pathway that converts pantothenate and cysteine into coenzyme A, the universal acyl carrier of the cell. Its rate-limiting PANK step, bifunctional COASY enzyme and compartmentalized organization make it a rich system for studying metabolic regulation, and its links to NBIA, CoPAN, ferroptosis and microbial metabolism give it broad disease relevance. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with CoA profiling and multi-omics, provide the experimental toolkit needed to dissect this pathway and to translate its biology into therapeutic hypotheses.